Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Omega-3s in IV food help gut failure patients?

NCT ID NCT03869957

Disease control Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding omega-3 fatty acids to intravenous (IV) nutrition could reduce oxidative stress in 20 adults with intestinal failure, a condition where the gut cannot absorb enough nutrients. Participants received either standard IV nutrition or IV nutrition with omega-3s for 7 days. The main goal was to see changes in a blood marker of cell damage. This small, early trial aims to gather initial data on a potential way to improve care for people who rely on IV feeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omega-3 polyunsaturated fatty acids (n-3 PUFAs) given intravenously
What this could lead to
If it works, this could point toward a way to reduce oxidative stress and improve nutrition for people with intestinal failure.
What could go wrong
This is a very small, early study with only 20 participants. It only measured short-term markers, not long-term health outcomes, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Dec 2019

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted in the non-critical areas of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) with a nutritional risk between January 2019 and July 2020 will be considered eligible. * Patients with recent diagnosis of IF type II (an evolution \>28 days) originate from various gastrointestinal or systemic diseases (short bowel, intestinal fistula, intestinal dysmotility, mechanical obstruction, and extensive small bowel mucosal disease). Exclusion Criteria: * Patients with contraindications for PN * Patients with known allergies to the components of the PN formula * Severe liver or renal insufficiency * Uncontrolled diabetes mellitus * Certain acute and life-threatening conditions * Immunological diseases (such as autoimmune diseases, human immunodeficiency virus infection, cancer, etc.) * Those that take immunosuppressant medications * Severe hemorrhagic disorders * Pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intestinal failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic intestinal failure Intestinal Failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intestinal failure

Contacts and locations

Locations

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

    Mexico City, Tlalpan, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.